Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 6, 2003, Pages 618-622

  Bray, David ^a   Yu, Shu Zhen ^a   Koprowski II, Hilary ^a   Rhee, Juong ^a   Kumar, Sanjeev ^b   Pericle, Federica ^b   Suntharalingam, Mohan ^a   Van Echo, David A ^a   Li, Daqing ^a   O'Malley Jr , Bert W ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Urigen Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; HEAD AND NECK CARCINOMA; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LYMPH NODE METASTASIS; MALE; MOUSE; MOUTH; NONHUMAN; NONVIRAL GENE THERAPY; PLASMID; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTOKINES; GENE THERAPY; HEAD AND NECK NEOPLASMS; INTERFERON TYPE II; INTERLEUKIN-2; MICE; MODELS, ANIMAL; RADIOTHERAPY; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038242794     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.6.618     Document Type: Article

References (14)

1. Li D, Jiang W, Bishop J, Ralston R, O'Malley BW Jr. Combination surgery and nonviral interleukin-2 gene therapy for head and neck cancer. Clin Cancer Res. 1999;5:1551-1556.
2. American Cancer Society. Facts and Figures. Washington, DC: American Cancer Society, 2000. Available at: http://www.cancer.org/docroot/stt_0_2000.asp ?sitearea=STT&level-1. Accessed February 19, 2003.
3. Gleich LL. Gene therapy for head and neck cancer. Laryngoscope. 2000;110: 708-726.
4. O'Malley BW, Li D, Buckner A, et al. Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer. Laryngoscope. 1999;109:389-395.
5. Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res. 1998;4: 835-845.
6. Pirollo KF, Hao Z, Rait A, et al. P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene. 1997;14:1735-1746.
7. Dezso B, Haas GP, Hamzavi F, et al. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases. Clin Cancer Res. 1996;2:1543-1552.
8. Younes E, Haas GP, Dezso B, et al. Radiation-induced effects on murine kidney tumor cells: role in the interaction of local irradiation and immunotherapy. J Urol. 1995;153:2029-2033.
9. Li D, Zeiders JW, Liu S, et al. Combination nonviral cytokine gene therapy for head and neck cancer. Laryngoscope. 2001;111:815-820.
10. O'Malley BW Jr, Cope K, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg. 1997;123:20-24.
11. Atkinson G, Hall SJ. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology. 1999;54:1098-1104.
12. Hendry JH, West CML. Apoptosis and mitotic cell death: their relative contribution to normal-tissue and tumour radiation response. Int J Radiat Biol. 1997;71: 709-719.
13. Komada Y, Zhou Y, Zhang X, et al. Fas/Apo-1(CD95)-mediated cytotoxicity is responsible for apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Br J Haematol. 1997;96:147-157.
14. Heusal JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell. 1994;76:977-987.